Novartis Pharma Corp v. Cipla USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novartis Pharmaceuticals Corporation, Novartis Technology LLC, The Medicines Company, and Alnylam Pharmaceuticals, Inc. (Delaware & Massachusetts)
  • Defendant: Cipla USA Inc. (Delaware) and Cipla Ltd. (India)
  • Plaintiff's Counsel: McCarter & English, LLP; Williams & Connolly LLP
• Case Identification: 1:26-cv-00272, D. Del., 03/13/2026
• Venue Allegations: Venue is alleged to be proper as Defendant Cipla USA Inc. is a Delaware corporation, and Defendant Cipla Ltd. is subject to personal jurisdiction in the district.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the cholesterol-lowering drug LEQVIO® constitutes an act of infringement of three U.S. patents related to RNA interference (RNAi) compositions and methods of use.
• Technical Context: The technology involves using small interfering RNA (siRNA) to inhibit the expression of the PCSK9 gene, which plays a role in regulating LDL cholesterol levels.
• Key Procedural History: This is a Hatch-Waxman Act litigation initiated in response to a notification letter from Cipla, dated January 28, 2026, which announced the filing of ANDA No. 220297 and asserted that the patents-in-suit are invalid and/or not infringed.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,125,369 - "PCSK9 iRNA compositions and methods of use thereof"

The Invention Explained

• Problem Addressed: The patent addresses the need for effective treatments for diseases associated with the PCSK9 gene, such as hypercholesterolemia, noting that elevated cholesterol levels contribute to atherosclerosis, which can lead to myocardial infarction or stroke '369 Patent, col. 2:20-49
• The Patented Solution: The invention provides double-stranded RNAi agents designed to inhibit the expression of the PCSK9 gene. These agents are composed of a sense strand and a complementary antisense strand with specific lengths and chemical modifications. The solution includes conjugating a ligand, such as a GalNAc derivative, to the RNAi agent to facilitate targeted delivery within the body '369 Patent, abstract '369 Patent, col. 2:50-68
• Technical Importance: The invention represents a therapeutic approach using RNA interference to silence a specific gene (PCSK9) involved in cholesterol metabolism, offering a mechanism distinct from traditional small-molecule or antibody-based therapies '369 Patent, col. 2:20-25

Key Claims at a Glance

• The complaint exemplifies claim 52 as being infringed Compl. ¶36 Claim 52 is a composition claim dependent on a chain of other claims leading back to independent claim 1.
• The essential elements of asserted example claim 52 are:
  • A pharmaceutical composition comprising the double stranded RNAi agent of claim 51.
  • The sense strand comprises the specific nucleotide sequence of SEQ ID NO:1657.
  • The antisense strand comprises the specific nucleotide sequence of SEQ ID NO:1663.
  • The composition includes specific chemical modifications (2'-O-methyl and 2'-fluoro), linkages (phosphorothioate), and a specific N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol ligand (L96).
• The complaint notes that Cipla's notice letter did not contest infringement of claims 1-52, 54-63, and 65-85 of the patent on any basis other than alleged invalidity Compl. ¶39

U.S. Patent No. 10,851,377 - "Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder"

The Invention Explained

• Problem Addressed: The patent addresses the need for methods of treating disorders that benefit from reducing PCSK9 expression, such as hyperlipidemia and hypercholesterolemia '377 Patent, col. 2:53-56
• The Patented Solution: The invention is a method for inhibiting PCSK9 expression in a human subject by subcutaneously administering a specific fixed dose (between 275 mg and 325 mg) of a particular double-stranded RNAi agent conjugated to a GalNAc ligand. This provides a defined therapeutic regimen for clinical use '377 Patent, abstract '377 Patent, col. 3:1-10
• Technical Importance: The invention provides a specific, practical method of use for an RNAi therapeutic, defining a fixed-dose subcutaneous injection regimen that simplifies administration and improves patient compliance compared to weight-based or intravenous dosing.

Key Claims at a Glance

• The complaint asserts infringement of claim 1 Compl. ¶59
• The essential elements of independent claim 1 are:
  • A method of inhibiting the expression of a PCSK9 gene in a human subject.
  • The method comprises subcutaneously administering a fixed dose of 275 mg to 325 mg of a double stranded RNAi agent.
  • The RNAi agent has a sense strand with the nucleotide sequence of SEQ ID NO: 687 and an antisense strand with the nucleotide sequence of SEQ ID NO: 688.
  • The RNAi agent includes specified chemical modifications (2'-O-methyl, 2'-fluoro, etc.).
  • The RNAi agent is conjugated to a N-acetylgalactosamine (GalNAc)3 ligand.
• The complaint notes that Cipla's notice letter did not contest infringement of claims 1-30 on any basis other than alleged invalidity Compl. ¶63

U.S. Patent No. 12,460,206 - "PCSK9 iRNA compositions and methods of use thereof"

Technology Synopsis

This patent claims a pharmaceutical composition comprising a double-stranded RNAi agent that inhibits PCSK9 expression. The claims define the specific nucleotide sequences for the sense and antisense strands and require a ligand to be conjugated to the 3'-end of the sense strand, all within a sterile aqueous solution '206 Patent, claim 1 This composition is intended for treating PCSK9-associated diseases like hyperlipidemia '206 Patent, col. 2:50-55

Asserted Claims

The complaint asserts infringement of claim 1 Compl. ¶83

Accused Features

The accused product is alleged to be a pharmaceutical composition containing inclisiran, which has the claimed nucleotide sequences and ligand structure, in a sterile aqueous solution Compl. ¶84 Compl. ¶85

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Cipla's ANDA Product," identified as a generic version of LEQVIO® (inclisiran) injection, 284 mg/1.5 mL, for which Cipla submitted ANDA No. 220297 to the FDA Compl. ¶1 Compl. ¶2

Functionality and Market Context

• The complaint alleges, based on Cipla's notice letter, that the ANDA product contains inclisiran, which is a double-stranded RNAi agent designed to inhibit the expression of PCSK9 Compl. ¶37 Compl. ¶61 Compl. ¶84 The complaint provides the specific nucleotide sequences, chemical modifications, and ligand structure of the inclisiran molecule in the accused product Compl. ¶38 Compl. ¶62 Compl. ¶85 The product is described as a sterile aqueous solution for injection Compl. ¶85
• The accused product is intended to be a generic equivalent to the branded drug LEQVIO®, which is used to reduce low-density lipoprotein cholesterol (LDL-C) Compl. ¶25 Compl. ¶26 The filing of the ANDA itself is the statutorily defined act of infringement under 35 U.S.C. § 271(e)(2)(A) that forms the basis of the lawsuit Compl. ¶35

IV. Analysis of Infringement Allegations

The complaint alleges that Cipla's ANDA product, containing inclisiran, will literally infringe the asserted claims. A notable feature of the complaint is its repeated assertion that Cipla's notice letter did not contest infringement on any basis other than the alleged invalidity of the patents-in-suit Compl. ¶39 Compl. ¶63 Compl. ¶86

'369 Patent Infringement Allegations

'377 Patent Infringement Allegations

Visual Evidence

The complaint provides a schematic of the inclisiran molecule, showing the ligand conjugated to the 3'-end of the sense strand, which corresponds to the structure claimed in the '206 patent Compl. p. 17

Identified Points of Contention

• Validity vs. Infringement: The primary point of contention, as framed by the complaint, appears to be patent validity rather than claim infringement. The allegation that Cipla has conceded infringement conditioned on validity Compl. ¶39 Compl. ¶63 Compl. ¶86 suggests the case may focus heavily on prior art, obviousness, enablement, and written description challenges.
• Scope Questions: The complaint's theory seems to rely on a direct, literal mapping of the accused product to the claims. This raises the question of whether Cipla, in its Answer, will identify any subtle structural or functional differences to argue for non-infringement, notwithstanding the complaint's characterization of Cipla's notice letter.
• Technical Questions: For the '377 patent, a key question will be evidentiary: what language in Cipla's proposed product labeling constitutes instruction or encouragement to perform the claimed method? The infringement analysis for this method patent will hinge on the contents of that label.

V. Key Claim Terms for Construction

While the complaint suggests infringement will be less contentious than validity, the construction of certain terms may still be crucial.

The Term: "a double stranded RNAi agent"

• Context and Importance: This term is the fundamental building block of all asserted claims. Its construction defines the scope of the protected technology. Practitioners may focus on this term because any interpretation that broadens or narrows its structural or functional requirements would impact the entire case.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specifications provide general definitions, stating an "iRNA" is an agent containing RNA that "mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway" '369 Patent, col. 13:58-63
  • Evidence for a Narrower Interpretation: The patents describe specific embodiments with particular lengths, chemical modification patterns, and ligand conjugations. A defendant could argue that the term, in the context of the claims, should be limited to agents possessing the specific structural features disclosed as critical to the invention's success, such as the specific GalNAc ligand shown '369 Patent, Figure 5 '369 Patent, col. 5:5-33

The Term: "fixed dose" (['377 Patent, claim 1](https://ex:cit:31))

• Context and Importance: This term is central to the asserted method claim of the '377 patent. The accused product is a pre-filled syringe with a fixed dose of 284 mg Compl. ¶1 The construction of this term will determine whether Cipla's product, as intended to be used, falls within the claimed method.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language itself provides a clear numerical range: "275 mg to 325 mg." A plain reading suggests any single administration within this range, not adjusted for patient weight, would meet the limitation. The specification also refers to administering the RNAi agent "as a fixed dose," distinguishing it from weight-based dosing '377 Patent, col. 28:13-17
  • Evidence for a Narrower Interpretation: The specification discusses various dosing regimens, including a "loading phase" followed by a "maintenance phase" '377 Patent, col. 3:28-49 A defendant might argue that the term "fixed dose" must be read in the context of a complete regimen as described, although independent claim 1 does not explicitly require a multi-part regimen.

VI. Other Allegations

Indirect Infringement

The complaint alleges both active inducement and contributory infringement for all three patents-in-suit Compl. ¶45 Compl. ¶69 Compl. ¶92 The inducement allegation is based on the assertion that Cipla's proposed product labeling will instruct or encourage physicians and patients to use the generic product in an infringing manner, which is particularly relevant for the method claims of the '377 patent Compl. ¶60 Compl. ¶68 Compl. ¶91 Contributory infringement is alleged on the basis that the product is not a staple article of commerce and lacks substantial non-infringing uses Compl. ¶42 Compl. ¶66 Compl. ¶89

Willful Infringement

The complaint does not use the term "willful infringement" but does allege that Cipla has knowledge of the patents and a "specific intent to infringe" Compl. ¶41 Compl. ¶65 Compl. ¶88 These allegations are based on Cipla's actions after receiving notice via the Hatch-Waxman process. The prayer for relief also requests a declaration that this is an "exceptional case" and an award of attorneys' fees pursuant to 35 U.S.C. § 285, a remedy often associated with findings of willfulness or litigation misconduct Compl., Prayer for Relief ¶e

VII. Analyst's Conclusion: Key Questions for the Case

This litigation, as framed by the Plaintiffs, appears poised to revolve around the following central questions:

• A core issue will be one of patent validity: Given the complaint's assertion that Cipla has effectively conceded literal infringement, can the highly specific composition and method claims of the patents-in-suit withstand the anticipated invalidity challenges based on prior art, written description, or enablement?
• A key evidentiary question will be one of induced infringement: What specific language and instructions will be contained in Cipla's proposed FDA label, and will that language be sufficient to prove that Cipla actively encouraged or promoted the specific, patented method of administration claimed in the '377 patent?
• A central dispute may be one of characterization and intent: Will Cipla's pre-suit certification of non-infringement and invalidity, followed by the continuation of its efforts to market a generic product post-filing, support a finding of an "exceptional case" warranting enhanced damages or attorneys' fees?